Zhou Tian, Hu Minlu, Cost Marilyn, Poloyac Samuel, Rohan Lisa
1 Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh , Pittsburgh, Pennsylvania.
AIDS Res Hum Retroviruses. 2013 Nov;29(11):1496-503. doi: 10.1089/aid.2013.0032. Epub 2013 May 17.
Topical vaginal microbicides have been considered a promising option for preventing the male-to-female sexual transmission of HIV; however, clinical trials to date have not clearly demonstrated robust and reproducible effectiveness results. While multiple approaches may help enhance product effectiveness observed in clinical trials, increasing the drug exposure in lower genital tract tissues is a compelling option, given the difficulty in achieving sufficient drug exposure and positive correlation between tissue exposure and microbicide efficacy. Since many microbicide drug candidates are substrates of transporters and/or metabolizing enzymes, there is emerging interest in improving microbicide exposure and efficacy through local modulation of transporters and enzymes in the female lower genital tract. However, no systematic information on transporter/enzyme expression is available for ectocervical and vaginal tissues of premenopausal women, the genital sites most relevant to microbicide drug delivery. The current study utilized reverse transcriptase polymerase chain reaction (RT-PCR) to examine the mRNA expression profile of 22 transporters and 19 metabolizing enzymes in premenopausal normal human ectocervix and vagina. Efflux and uptake transporters important for antiretroviral drugs, such as P-gp, BCRP, OCT2, and ENT1, were found to be moderately or highly expressed in the lower genital tract as compared to liver. Among the metabolizing enzymes examined, most CYP isoforms were not detected while a number of UGTs such as UGT1A1 were highly expressed. Moderate to high expression of select transporters and enzymes was also observed in mouse cervix and vagina. The implications of this information on microbicide research is also discussed, including microbicide pharmacokinetics, the utilization of the mouse model in microbicide screening, as well as the in vivo functional studies of cervicovaginal transporters and enzymes.
局部阴道杀菌剂被认为是预防艾滋病毒从男性向女性性传播的一个有前景的选择;然而,迄今为止的临床试验尚未明确显示出强大且可重复的有效性结果。虽然多种方法可能有助于提高临床试验中观察到的产品有效性,但鉴于在实现足够的药物暴露方面存在困难,以及组织暴露与杀菌剂疗效之间的正相关关系,增加下生殖道组织中的药物暴露是一个有吸引力的选择。由于许多杀菌剂候选药物是转运蛋白和/或代谢酶的底物,因此人们越来越有兴趣通过局部调节女性下生殖道中的转运蛋白和酶来提高杀菌剂的暴露量和疗效。然而,对于绝经前女性的宫颈外口和阴道组织(与杀菌剂药物递送最相关的生殖部位),尚无关于转运蛋白/酶表达的系统信息。当前的研究利用逆转录聚合酶链反应(RT-PCR)来检测绝经前正常人类宫颈外口和阴道中22种转运蛋白和19种代谢酶的mRNA表达谱。与肝脏相比,对抗逆转录病毒药物重要的外排和摄取转运蛋白,如P-糖蛋白、乳腺癌耐药蛋白、有机阳离子转运体2和等效核苷转运体1,在下生殖道中呈中度或高度表达。在所检测的代谢酶中,大多数细胞色素P450同工酶未被检测到,而一些尿苷二磷酸葡萄糖醛酸转移酶,如尿苷二磷酸葡萄糖醛酸转移酶1A1,呈高度表达。在小鼠的宫颈和阴道中也观察到了所选转运蛋白和酶的中度至高度表达。还讨论了这些信息对杀菌剂研究的影响,包括杀菌剂药代动力学、小鼠模型在杀菌剂筛选中的应用,以及宫颈阴道转运蛋白和酶的体内功能研究。